StockData
Tandem Diabetes Care Inc logo

Tandem Diabetes Care Inc (TNDM) stock

TNDMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3030% below fair value
$17.06−1.42 (-7.68%)

Close on Nov 17, 2026Market cap $1.19BP/E –Yield –

Earnings

Tandem Diabetes Care's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 18, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$283.70M
+13.8% on a year earlier
EPS, Q3 FY2026
-$0.10
-$0.31 a year earlier
Latest guidance
Issued
Nov 5, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Tandem Diabetes Care's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 18, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close$283.70M+13.8%-$0.10Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026during market hours$254.60M+5.8%-$0.31Release
Q1 FY2026ended Mar 31, 2026May 7, 2026during market hours$247.20M+5.5%–Release
Q4 FY2025ended Dec 31, 2025Feb 19, 2026during market hours$290.40M+2.8%–Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours$249.30M+2.2%-$0.31Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025during market hours$240.70M+8.5%-$0.78Release
Q1 FY2025ended Mar 31, 2025Apr 30, 2025during market hours$234.40M+22.3%-$1.97Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025during market hours$282.60M+43.6%$0.01Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024during market hours$244.00M+31.4%–Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024during market hours$221.90M+13.3%-$0.47Release
Q1 FY2024ended Mar 31, 2024May 2, 2024during market hours$191.70M+13.2%-$0.65Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Tandem Diabetes Care's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
SalesFY2026$1.07B – $1.09B–NewNov 5, 2026
SalesFY2026$1.07B – $1.09B$1.07B – $1.09BRaisedAug 6, 2026
SalesGAAPFY2026$730.00M – $745.00M–LoweredFeb 19, 2026
Gross marginGAAPFY202656% – 57%–NewNov 5, 2026
Gross marginFY202656% – 57%56% – 57%ReaffirmedAug 6, 2026
Gross marginGAAPFY202656% – 57%–NewFeb 19, 2026
Adjusted EBITDA marginnon-GAAPFY20265% – 6%–NewNov 5, 2026
Adjusted EBITDA marginnon-GAAPFY20265% – 6%–NewFeb 19, 2026
Adjusted EBITDA marginnon-GAAPFY20265% – 6%5% – 6%ReaffirmedAug 6, 2026
depreciation and amortization expenseFY2026$20.00M$20.00MLoweredAug 6, 2026
Non-cash charges included in cost of goods sold and operating expensesFY2026$85.00M$100.00MRaisedAug 6, 2026
non-cash, stock-based compensation expenseFY2026$65.00M$80.00MLoweredAug 6, 2026

Guidance vs results

The last range Tandem Diabetes Care gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$1.00B$1.01BΣ4QAbove range
Q1 FY2025Revenue$219.00M – $224.00M$234.40MAbove range
Q3 FY2024Revenue$222.00M – $225.00M$244.00MAbove range
Q2 FY2024Revenue$205.00M$221.90MAbove range
Q1 FY2024Revenue$175.00M$191.70MAbove range
Q3 FY2023Revenue$190.00M$185.62MBelow range

Guidance history

Every forecast Tandem Diabetes Care put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026Adjusted EBITDA marginFY20265% – 6%New
Nov 5, 2026Gross marginFY202656% – 57%New
Nov 5, 2026SalesFY2026$1.07B – $1.09BNew
Aug 6, 2026Gross marginFY202656% – 57%Reaffirmed
Aug 6, 2026Adjusted EBITDA marginFY20265% – 6%Reaffirmed
Aug 6, 2026Non-cash charges included in cost of goods sold and operating expensesFY2026$85.00MRaised
Aug 6, 2026non-cash, stock-based compensation expenseFY2026$65.00MLowered
Aug 6, 2026depreciation and amortization expenseFY2026$20.00MLowered
Aug 6, 2026SalesFY2026$1.07B – $1.09BRaised
Aug 6, 2026U.S. salesFY2026$730.00M – $745.00MLowered
Aug 6, 2026International salesFY2026$335.00M – $340.00MLowered
May 7, 2026Gross marginFY202656% – 57%New
May 7, 2026Adjusted EBITDA marginFY20265% – 6%New
May 7, 2026Non-cash charges included in cost of goods sold and operating expensesFY2026$100.00MRaised
May 7, 2026non-cash, stock-based compensation expenseFY2026$80.00MLowered
May 7, 2026depreciation and amortization expenseFY2026$20.00MLowered
May 7, 2026SalesFY2026$1.07B – $1.09BNew
May 7, 2026United States salesFY2026$730.00M – $745.00MLowered
May 7, 2026International salesFY2026$335.00M – $340.00MLowered
Feb 19, 2026Adjusted EBITDA marginFY20265% – 6%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Tandem Diabetes Care filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. News
  5. News
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. News
  15. News

See a number that looks wrong?